Seltorexant
Clinical data | |
---|---|
Other names | MIN-202; JNJ-42847922; JNJ-922 |
Routes of administration | By mouth[1] |
Drug class | Orexin antagonist |
ATC code |
|
Legal status | |
Legal status | |
Pharmacokinetic data | |
Metabolism | CYP3A4[2] |
Elimination half-life | 2–3 hours[2] |
Identifiers | |
| |
JSmol) | |
| |
|
Seltorexant, also known by its developmental code names MIN-202 and JNJ-42847922, is an
orexin antagonist medication which is under development for the treatment of depression and insomnia.[3][2] It is a selective antagonist of the orexin OX2 receptor (2-SORA).[2][4][1] The medication is taken by mouth.[1] As of February 2022, seltorexant is in phase 3 clinical trials for treatment of major depressive disorder (MDD) and phase 2 trials for treatment of insomnia.[3] It was also under investigation for the treatment of sleep apnea, but no recent development has been reported for this indication.[3] Seltorexant is under development by Minerva Neurosciences and Johnson & Johnson's Janssen Pharmaceuticals.[3]
Seltorexant is being explored at doses of 5 to 80 mg.abdominal discomfort, and nightmares.[2]
Seltorexant shows over 100-fold greater
small-molecule compound and is structurally related to other clinically used orexin receptor antagonists.[5][2]
See also
- Vornorexant – another investigational short-acting orexin receptor antagonist
- List of investigational antidepressants § Orexin receptor antagonists
- List of investigational sleep drugs § Orexin receptor antagonists